Orforglipron (Foundayo) Explained: The Non-Peptide GLP-1 Pill

When people hear “GLP-1 pill,” many assume it is simply an injection squeezed into tablet form. For one of the two pills approved for weight management in the US, that is roughly true: the Wegovy pill contains semaglutide, the same peptide as the weekly shot. Orforglipron, sold as Foundayo, is different. It is a small, non-peptide molecule designed from the start to be swallowed, and that one chemical difference explains most of what is distinctive about it, from its flexible dosing to its particular list of drug interactions.

This guide explains what orforglipron is, how it works, what its clinical trials actually showed, its side effects and warnings, how it is taken, what it costs and the questions worth raising with a clinician.

The short answer

Orforglipron is a once-daily GLP-1 receptor agonist pill. The FDA approved it as Foundayo on April 1, 2026, for adults with obesity, or with overweight and at least one weight-related condition, to be used with a reduced-calorie diet and more physical activity. In its main trial in adults without diabetes, the top dose produced an average weight loss of 11.1% over 72 weeks, compared with 2.1% on placebo. It can be taken any time of day, with or without food. Its side effects are mostly digestive and similar to other GLP-1 medicines, and it is not recommended alongside any other GLP-1 drug.

What orforglipron is, and why “non-peptide” matters

GLP-1 is a natural gut hormone made of a short chain of amino acids, a peptide. Semaglutide, liraglutide and tirzepatide are all engineered peptides that resemble it. Peptides work well in the body, but the digestive system is built to break them down, which is why most GLP-1 medicines are injected. If you are new to this class, our explainer on what a GLP-1 medication is covers the basics.

The Wegovy pill gets around the problem with a large daily dose of semaglutide and an absorption enhancer, and even then only a small fraction is absorbed, which is why it comes with strict empty-stomach rules. We explain that approach in oral semaglutide explained.

Orforglipron takes another route. It is a small-molecule drug, built more like a conventional pill such as a blood pressure or cholesterol tablet. According to the Foundayo label:

• Its average absolute bioavailability was 77% after a 0.8 mg dose, meaning most of the swallowed dose reached the bloodstream.
• There was no clinically relevant effect of food on how much was absorbed.
• Peak blood levels occur 4 to 8 hours after a dose, steady levels are reached after about a week of daily dosing, and the half-life is about 29 to 49 hours.
• It is broken down mainly by a liver enzyme called CYP3A4, and almost all of it leaves the body in stool rather than urine.

That last point is the trade-off. Because it is processed like many ordinary pills, other medicines that speed up or slow down CYP3A4 can change how much orforglipron is in your blood. Peptide GLP-1 drugs do not have this issue in the same way.

Orforglipron was discovered by Chugai Pharmaceutical and licensed by Eli Lilly in 2018, according to Lilly. A YouTube explainer on its approval sums up the core idea well: instead of modifying a peptide to survive oral delivery, orforglipron is “inherently orally active.” The same video notes that it appears to activate the GLP-1 receptor in a slightly different way from peptide drugs, favoring some signaling pathways over others. That is an interesting laboratory finding, but so far it has not translated into obviously fewer side effects in people.

How it works in the body

Once in the bloodstream, orforglipron does the same basic job as other GLP-1 medicines. The label says it binds to and activates the human GLP-1 receptor, including in brain regions that regulate appetite. In practice that means:

• Lower appetite and less food intake, which the label says is the likely main driver of weight loss.
• Slower stomach emptying, which helps you feel full longer. The label notes this delay is largest after the first dose and fades over time.
• Better blood sugar control, because GLP-1 activation boosts insulin release when blood sugar is high.

The label also states that weight loss on Foundayo involved more fat loss than lean mass loss. For a deeper look at the biology shared across the class, see how GLP-1s work for weight loss.

One detail surprises people: orforglipron is not active in rats or mice. That is why its boxed warning about thyroid tumors is worded differently from other GLP-1 labels, as explained in the safety section below.

What the clinical trials showed

Foundayo’s approval rests mainly on two 72-week, double-blind, placebo-controlled trials called ATTAIN-1 and ATTAIN-2. In both, everyone also received lifestyle counseling on a reduced-calorie diet and at least 150 minutes a week of physical activity.

One technical note before the numbers: the trials used an investigational formulation dosed at 6, 12 and 36 mg. The FDA label presents the same results as the equivalent marketed doses of 5.5, 9 and 17.2 mg. So if you read the journal papers, you will see different dose numbers for the same groups.

ATTAIN-1: adults without diabetes

ATTAIN-1 enrolled 3,127 adults with obesity, or overweight plus a weight-related condition such as high blood pressure, abnormal cholesterol or sleep apnea. Their average starting weight was about 103 kg (227 pounds), and 64% were women. Results at 72 weeks, counting everyone who was randomly assigned whether or not they kept taking the drug:

Group	Average weight change	Lost at least 10%	Lost at least 20%
Placebo	-2.1%	13%	2.9%
Foundayo 5.5 mg	-7.4%	32.5%	5.9%
Foundayo 9 mg	-8.3%	39.8%	8.9%
Foundayo 17.2 mg	-11.1%	54.5%	18.4%

Source: Foundayo FDA label, Table 6 (intent-to-treat population).

Lilly’s approval announcement highlights a higher figure: people on the top dose who stayed on treatment lost an average of 12.4%, or about 27 pounds. Both numbers are legitimate. The 11.1% answers “what happens to everyone who starts,” while 12.4% answers “what happens if people keep taking it.” For context on what to expect month by month on GLP-1 medicines generally, see our GLP-1 weight loss timeline.

At the top dose, waist size fell by an average of 10 cm versus 3.1 cm with placebo, and systolic blood pressure fell 6.4 mm Hg versus 1.4 mm Hg. Triglycerides fell 20% versus 4%.

ATTAIN-2: adults with type 2 diabetes

People with type 2 diabetes tend to lose less weight on any GLP-1 medicine, and ATTAIN-2 was no exception. Among 1,613 adults with diabetes and a BMI of 27 or higher, average weight change at 72 weeks was -5.1%, -7.0% and -9.6% on the three doses, versus -2.5% on placebo. On the top dose, 45.6% lost at least 10% of their weight. HbA1c, a measure of average blood sugar, fell by 1.7 points from a starting average of about 8.1% on the top dose, versus 0.4 points on placebo.

Older adults

A post hoc analysis of people aged 65 or older in ATTAIN-1 found average weight changes of -7.9%, -11.3% and -13.0% across the three doses, versus -1.6% on placebo, with a safety profile described as generally consistent with other GLP-1 medicines. The label says no overall differences in safety or effectiveness were seen between people 65 or older and younger adults, though only 13% of treated participants were in that age group.

Keeping weight off after an injection: ATTAIN-MAINTAIN

A question many people ask is whether they could lose weight on a weekly injection and then switch to a pill. The ATTAIN-MAINTAIN trial, published in Nature Medicine in 2026, tested exactly that. Participants who had already lost weight on injectable tirzepatide or semaglutide in an earlier trial were randomly assigned to orforglipron or placebo for 52 weeks.

• Among people coming off tirzepatide, those on orforglipron kept about 75% of their earlier weight reduction, versus about 49% on placebo. On average they regained roughly 5 kg (about 11 pounds) over the year.
• Among people coming off semaglutide, those on orforglipron kept about 79%, versus about 38% on placebo, with an average regain of roughly 1 kg.

The authors note two important limits: the trial lasted only one year, and it had no group that simply stayed on the injection. So it shows orforglipron is much better than stopping treatment, but not whether it is as good as continuing the original medicine. Our guide to maintaining weight loss covers the wider evidence on what happens after GLP-1 treatment changes or stops.

Head-to-head with oral semaglutide in diabetes

In ACHIEVE-3, published in The Lancet in 2026, 1,698 adults with type 2 diabetes on metformin were randomly assigned to orforglipron or oral semaglutide at the doses used for diabetes. Over 52 weeks, both orforglipron doses lowered HbA1c more than both semaglutide doses. Lilly reported that the top orforglipron dose produced 9.2% weight loss versus 5.3% with oral semaglutide 14 mg among people who stayed on treatment.

There are caveats. The trial was open-label, it used diabetes doses of oral semaglutide rather than the higher 25 mg dose in the Wegovy pill, and digestive side effects, stopping because of side effects and increases in pulse rate were all higher with orforglipron. A commentary summarized in a diabetes-journal digest cautioned against reading the trial as proof that orforglipron is simply more effective than semaglutide. For a broader comparison of the two pills and the injections, see GLP-1 pills vs injections.

Heart safety

ACHIEVE-4 compared orforglipron with insulin glargine in 2,749 adults with type 2 diabetes and established heart or kidney disease. Over a median of about two years, major cardiovascular events occurred in 4.2% on orforglipron and 5.0% on insulin (hazard ratio 0.84), which met the trial’s goal of showing orforglipron is not worse for heart safety. It did not prove a heart benefit, and unlike Wegovy, Foundayo is not approved to reduce cardiovascular risk. Some peptide GLP-1 drugs, such as semaglutide, have that approval based on dedicated outcome trials; our semaglutide clinical trial results explain that evidence.

Side effects

Orforglipron’s side effects look like those of the rest of the class. In the pooled ATTAIN trials, the label lists these as most common:

Side effect	Placebo	Foundayo 5.5 mg	Foundayo 9 mg	Foundayo 17.2 mg
Nausea	10%	26%	34%	35%
Constipation	9%	20%	27%	24%
Diarrhea	11%	21%	23%	25%
Vomiting	4%	13%	21%	24%
Indigestion	4%	12%	16%	13%
Headache	7%	8%	9%	9%

Source: Foundayo FDA label, Table 1.

Overall, digestive side effects affected 60% to 69% of people on Foundayo versus 37% on placebo. Most were mild or moderate, and nausea, vomiting and diarrhea were most common during the dose-increase period and became less frequent over time. About 8% of people stopped because of side effects, versus 3% on placebo, mostly because of digestive problems.

Other findings from the label worth knowing:

• Heart rate: average increases of 4 to 5 beats per minute, versus 0.5 with placebo.
• Low blood pressure: 2% versus 0.5%, more often in people already on blood pressure medicines.
• Hair loss: reported in 7% of women and 0.9% of men on Foundayo, and linked with weight loss.
• Low blood sugar: mainly a concern for people with diabetes, especially when combined with a sulfonylurea or insulin.

Practical strategies for the digestive effects are in our guides to GLP-1 nausea and GLP-1 constipation and diarrhea, and in our guide to managing side effects.

Serious warnings

Foundayo carries the same categories of serious warnings as other GLP-1 medicines: pancreatitis, severe digestive reactions, kidney injury from dehydration, gallbladder problems, serious allergic reactions, worsening of diabetic eye disease with rapid blood sugar improvement, and a risk of inhaling stomach contents during anesthesia or deep sedation. Tell anyone planning a procedure that you take it. Gallbladder issues are covered in detail in GLP-1 gallbladder problems.

The boxed warning about thyroid C-cell tumors is phrased with an unusual nuance. Peptide GLP-1 drugs cause these tumors in rodents. Orforglipron is not active in rats or mice and did not produce tumors in them, but the label says the relevance of the rodent findings to people “has not been determined.” It is still contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2.

What about the liver?

Liver safety is the question hanging over small-molecule GLP-1 pills. In April 2025, Pfizer discontinued its own candidate, danuglipron, after one participant in a dose-optimization study had a possible drug-induced liver injury, which resolved after stopping the drug. For orforglipron, a pooled analysis of seven phase 3 trials including more than 11,000 participants found no cases meeting criteria for drug-induced liver injury, and liver-related adverse events were balanced with comparators. The label says Foundayo is not recommended for people with severe liver impairment, because blood levels rose about 4.6-fold in that group.

How Foundayo is taken

The label sets a step-by-step dose schedule to reduce digestive side effects. People start at 0.8 mg once daily, move to 2.5 mg after at least 30 days, then to 5.5 mg after at least another 30 days. From there, a prescriber may increase to 9 mg, 14.5 mg and finally the maximum of 17.2 mg, each after at least 30 days, based on response and tolerability.

Feature	What the label says
Timing	Once daily, any time of day
Food and water	With or without food; no water limit
How to swallow	Whole; do not break, crush or chew
Missed dose	Take as soon as possible; do not double up
Long gap	Restart at a lower dose after 7 or more missed days in a row
Storage	Room temperature, 68°F to 77°F

This guide describes the label for general understanding only; your prescriber decides your actual dose and pace.

Drug interactions to raise with your prescriber

Because orforglipron is processed by CYP3A4 and slows stomach emptying, the label lists specific interactions:

• Strong CYP3A4 inhibitors cap Foundayo at 9 mg a day, and those that also block a liver transporter called OATP1B, such as ritonavir, should be avoided.
• Strong CYP3A4 inducers should be avoided because they can make Foundayo less effective.
• Simvastatin should not exceed 20 mg a day, because Foundayo doubled exposure to its active form.
• Birth control pills: switch to a non-oral method or add a barrier method for 30 days after starting and after each dose increase. Foundayo should be stopped if pregnancy occurs.
• Insulin or sulfonylureas: doses may need to be lowered to reduce the risk of low blood sugar.

Your pharmacist can tell you which of your medicines fall into these groups. No dose change is needed for kidney impairment, according to the label. Supplements and alcohol are worth mentioning to your clinician too; our article on alcohol and GLP-1s covers drinking during treatment.

Who might consider orforglipron

Foundayo is approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Our guide to who qualifies for GLP-1 weight-loss treatment explains these criteria. Within that group, a clinician might discuss Foundayo with people who:

• Prefer a pill to injections, or have a fear of needles.
• Want a daily routine without empty-stomach rules, perhaps because they take several morning medicines.
• Travel often or lack reliable refrigeration.
• Have lost weight on an injection and want to discuss a maintenance option, keeping in mind the limits of ATTAIN-MAINTAIN.

People who want the largest average weight loss seen in trials may lean toward injectable tirzepatide, which averaged about 21% at its top dose in its main trial; see tirzepatide clinical trial results. People with established heart disease may prefer a medicine with a proven cardiovascular benefit. Anyone taking interacting medicines needs a careful review first.

Cost and access

At approval, Lilly said Foundayo would be available through its direct pharmacy first, followed by US retail pharmacies and telehealth providers. According to Lilly’s savings page, checked October 22, 2026, regular self-pay prices for a 30-day supply are $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg. The two highest doses drop to $299 if each refill is completed within 45 days of the previous delivery. Lilly also lists some temporary reductions on lower doses through December 31, 2026. Lilly says commercially insured patients whose plans cover Foundayo may pay as little as $25 a month with a savings card, and said eligible Medicare Part D patients may be able to get it for $50 a month from July 1, 2026.

Prices and programs change often, and insurance coverage for weight-loss drugs varies widely. Read does insurance cover GLP-1s for weight loss? and our GLP-1 cost guide before deciding.

A safety note: Foundayo is a prescription medicine. Products sold online as “orforglipron” without a prescription, including those labeled “for research use only,” are not FDA-approved Foundayo, and their contents and quality are unknown.

Common myths, corrected

Myth	What the evidence shows
“It’s just Ozempic in a pill.”	No. Orforglipron is a different, non-peptide molecule. The Wegovy pill is the semaglutide pill.
“No food rules means no rules.”	Food does not matter, but the label lists real drug interactions and dose limits.
“Pills have fewer side effects than shots.”	Digestive side effects were common and broadly similar to other GLP-1 drugs.
“It doesn’t cause thyroid tumors, so the warning doesn’t apply.”	It did not cause tumors in rodents, where it is inactive, but human relevance is undetermined and the contraindications still apply.
“It protects your heart.”	ACHIEVE-4 showed heart safety versus insulin, not a proven heart benefit.

On X, posts about Foundayo swing between enthusiasm over its convenience and confusion about what it is. One post that circulated widely claimed the once-a-day limit exists because the pill “risks overloading the liver”; the label simply says not to take more than one tablet a day and gives no such reason, and the pooled liver-safety data were reassuring. Others correctly point out that orforglipron and oral semaglutide come with “completely opposite” dosing instructions despite sharing a drug class.

How to decide, with your clinician

Questions worth bringing to your appointment:

1. Based on my health history and goals, how does Foundayo compare with the Wegovy pill and the weekly injections?
2. Do any of my current medicines or supplements interact with it?
3. If I use birth control pills, what backup method should I use, and for how long?
4. How will we handle side effects during the first months of dose increases?
5. What should my nutrition and activity plan look like to protect muscle? Our guides on protein on GLP-1s and strength training on GLP-1s can help you prepare.
6. What will it cost me each month, at each dose?

To get started, see how to get a GLP-1 prescription, our first 30 days guide and the list of every FDA-approved GLP-1 for weight loss.

The bottom line

Orforglipron is the first small-molecule GLP-1 pill approved for weight management, and its chemistry is what sets it apart: it is well absorbed, can be taken any time with or without food, and needs no refrigeration. In trials, the top dose produced about 11% average weight loss over 72 weeks in adults without diabetes, with digestive side effects similar to other GLP-1 medicines. It appears to help people keep off much of the weight lost on injections compared with stopping treatment, and it showed heart safety in people with diabetes, though not a proven heart benefit. Its drug interactions and contraception guidance make a full medication review essential. For many people, the best GLP-1 is the one they can take consistently, chosen with a clinician who knows their whole health picture.

Explore more in the Oral & New GLP-1s hub, the GLP-1 Guide hub and the Tirzepatide hub.

Medical disclaimer: Weightomics publishes general health information for education only. It is not a substitute for professional medical advice, diagnosis or treatment. Never start, stop or change a medication, diet or exercise program without talking to a licensed clinician.